- Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
-
Martin JY, Urban RR, Liao JB, Goff BA
- KMID: 2374249
- J Gynecol Oncol.
- 2016 Sep;27(5):e47.
- doi: 10.3802/jgo.2016.27.e47
OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer... -
- CITED
-
- Close
- SHARE
-
- Close
